AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo

AbbVie (ABBV) secured FDA approval for Juvmo (tavapadon), a once-daily oral dopamine receptor agonist for Parkinson's disease. The drug can be used as monotherapy or in combination with levodopa and marks the first dopaminergic breakthrough for the disease in decades.

ABBV projects Juvmo will contribute to more than $5 billion in combined peak sales alongside its Vyalev and Duopa franchises, bolstering the company's neuroscience division. The approval expands ABBV's treatment portfolio in a therapeutic area with limited recent innovation.

Juvmo's mechanism as a dopamine receptor agonist offers an alternative approach to managing Parkinson's symptoms, potentially capturing market share in a patient population exceeding several million in the United States alone. The once-daily oral formulation may provide a convenience advantage over existing therapies.